Breast cancer takes the first place in the structure of morbidity and mortality from malignant neoplasms in women. It indicates the problem of patients and doctors’ unsatisfied needs in the treatment of this disease. Some types of cancer, such as melanoma, bladder or renal cell carcinoma, demonstrated a long-term response to immunotherapy, however, breast tumors did not show the same efficacy, because breast cancer is immunologically "cold", it is weakly infiltrated with T cells and causes a weak immune response. The causes of immune silence in breast cancer are not fully defined and this knowledge gap threatens the life and health of hundreds and thousands of patients. Thus, further studies of new therapeutic agents, mixed agonists/antagonists of nanomolecules MSC-428 in multitarget immunotherapy targeted at reprogramming the activity of 8 receptor proteins, are crucial for the development of the most effective cancer treatment strategies. According to the study, it can be stated that MSC-428 application in the combination with neoadjuvant chemotherapy (NAC) demonstrated the greatest clinical benefits for cancer patients, by involving the immune system in the process of tumor destruction. It made the tumor immunologically “hot”, by enhancing its infiltration with T cells, reducing the risk of metastasis, inhibiting several very important immune checkpoint proteins, thereby increasing the cytotoxic effect of T-lymphocytes and, accordingly, the duration of disease-free survival of patients.